Literature DB >> 27672056

Molecular Subtypes of Breast Cancer: Long-term Incidence Trends and Prognostic Differences.

Marit Valla1, Lars Johan Vatten2, Monica Jernberg Engstrøm2,3, Olav Anton Haugen4, Lars Andreas Akslen5,6, Johan Håkon Bjørngaard2,7, Anne Irene Hagen3, Borgny Ytterhus4, Anna Mary Bofin4, Signe Opdahl2.   

Abstract

BACKGROUND: Secular trends in incidence and prognosis of molecular breast cancer subtypes are poorly described. We studied long-term trends in a population of Norwegian women born 1886-1977.
METHODS: A total of 52,949 women were followed for breast cancer incidence, and 1,423 tumors were reclassified into molecular subtypes using IHC and in situ hybridization. We compared incidence rates among women born 1886-1928 and 1929-1977, estimated age-specific incidence rate ratios (IRR), and performed multiple imputations to account for unknown subtype. Prognosis was compared for women diagnosed before 1995 and in 1995 or later, estimating cumulative risk of death and HRs.
RESULTS: Between 50 and 69 years of age, incidence rates of Luminal A and Luminal B (HER2-) were higher among women born in 1929 or later, compared with before 1929 [IRRs 50-54 years; after imputations: 3.5; 95% confidence interval (CI), 1.8-6.9 and 2.5; 95% CI, 1.2-5.2, respectively], with no clear differences for other subtypes. Rates of death were lower in women diagnosed in 1995 or later, compared to before 1995, for Luminal A (HR 0.4; 95% CI, 0.3-0.5), Luminal B (HER2-; HR 0.5; 95% CI, 0.3-0.7), and Basal phenotype (HR 0.4; 95% CI, 0.2-0.9).
CONCLUSIONS: We found a strong secular incidence increase restricted to Luminal A and Luminal B (HER2-) subtypes, combined with a markedly improved prognosis for these subtypes and for the Basal phenotype. IMPACT: This study documents a clear secular increase in incidence and a concomitant improved prognosis for specific molecular breast cancer subtypes. Cancer Epidemiol Biomarkers Prev; 25(12); 1625-34. ©2016 AACR. ©2016 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27672056     DOI: 10.1158/1055-9965.EPI-16-0427

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  15 in total

1.  Demographic changes in breast cancer incidence, stage at diagnosis and age associated with population-based mammographic screening.

Authors:  Francys C Verdial; Ruth Etzioni; Catherine Duggan; Benjamin O Anderson
Journal:  J Surg Oncol       Date:  2017-02-14       Impact factor: 3.454

2.  Feasibility of analyzing DNA copy number variation in breast cancer tumor specimens from 1950 to 2010: how old is too old?

Authors:  Nancy Krieger; Sheida Nabavi; Pamela D Waterman; Ninah S Achacoso; Luana Acton; Stuart J Schnitt; Laurel A Habel
Journal:  Cancer Causes Control       Date:  2018-02-09       Impact factor: 2.506

3.  Characterization of FGD5 Expression in Primary Breast Cancers and Lymph Node Metastases.

Authors:  Marit Valla; Patricia G Mjønes; Monica J Engstrøm; Borgny Ytterhus; Diana L Bordin; Barbara van Loon; Lars A Akslen; Lars J Vatten; Signe Opdahl; Anna M Bofin
Journal:  J Histochem Cytochem       Date:  2018-07-27       Impact factor: 2.479

4.  ZNF703 gene copy number and protein expression in breast cancer; associations with proliferation, prognosis and luminal subtypes.

Authors:  Elise Klæstad; Joanna Ewa Sawicka; Monica Jernberg Engstrøm; Borgny Ytterhus; Marit Valla; Anna Mary Bofin
Journal:  Breast Cancer Res Treat       Date:  2021-01-02       Impact factor: 4.872

5.  The association of women's birth size with risk of molecular breast cancer subtypes: a cohort study.

Authors:  Marie S Sandvei; Signe Opdahl; Marit Valla; Pagona Lagiou; Ellen Veronika Vesterfjell; Tor Vikan Rise; Tina Syvertsen Overrein; Anette H Skjervold; Monica J Engstrøm; Anna M Bofin; Lars J Vatten
Journal:  BMC Cancer       Date:  2021-03-23       Impact factor: 4.430

6.  Morphology and genomic hallmarks of breast tumours developed by ATM deleterious variant carriers.

Authors:  Anne-Laure Renault; Noura Mebirouk; Laetitia Fuhrmann; Guillaume Bataillon; Eve Cavaciuti; Dorothée Le Gal; Elodie Girard; Tatiana Popova; Philippe La Rosa; Juana Beauvallet; Séverine Eon-Marchais; Marie-Gabrielle Dondon; Catherine Dubois d'Enghien; Anthony Laugé; Walid Chemlali; Virginie Raynal; Martine Labbé; Ivan Bièche; Sylvain Baulande; Jacques-Olivier Bay; Pascaline Berthet; Olivier Caron; Bruno Buecher; Laurence Faivre; Marc Fresnay; Marion Gauthier-Villars; Paul Gesta; Nicolas Janin; Sophie Lejeune; Christine Maugard; Sébastien Moutton; Laurence Venat-Bouvet; Hélène Zattara; Jean-Pierre Fricker; Laurence Gladieff; Isabelle Coupier; Georgia Chenevix-Trench; Janet Hall; Anne Vincent-Salomon; Dominique Stoppa-Lyonnet; Nadine Andrieu; Fabienne Lesueur
Journal:  Breast Cancer Res       Date:  2018-04-17       Impact factor: 6.466

7.  Do 21-Gene Recurrence Score Influence Chemotherapy Decisions in T1bN0 Breast Cancer Patients?

Authors:  Jing Yu; Jiayi Wu; Ou Huang; Jianrong He; Zhu Li; Weiguo Chen; Yafen Li; Xiaosong Chen; Kunwei Shen
Journal:  Front Oncol       Date:  2020-05-12       Impact factor: 6.244

8.  Acid-base transporters and pH dynamics in human breast carcinomas predict proliferative activity, metastasis, and survival.

Authors:  Nicolai J Toft; Trine V Axelsen; Helene L Pedersen; Marco Mele; Mark Burton; Eva Balling; Tonje Johansen; Mads Thomassen; Peer M Christiansen; Ebbe Boedtkjer
Journal:  Elife       Date:  2021-07-05       Impact factor: 8.140

9.  Trends in molecular subtypes of breast cancer: description of incidence rates between 2007 and 2012 from three French registries.

Authors:  Marion Cortet; Aurélie Bertaut; Florence Molinié; Simona Bara; Françoise Beltjens; Charles Coutant; Patrick Arveux
Journal:  BMC Cancer       Date:  2018-02-07       Impact factor: 4.430

10.  T1-2N1M0 triple-negative breast cancer patients from the SEER database showed potential benefit from post-mastectomy radiotherapy.

Authors:  Xueying Wang; Yingying Xu; Shanshan Guo; Jiaxin Zhang; Masanobu Abe; Haosheng Tan; Shaojun Wang; Ping Chen; Liang Zong
Journal:  Oncol Lett       Date:  2019-11-21       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.